Research groups

GE03 Inflammatory immune-mediated cutaneous diseases

The final goal of our team, established since 2015 as an emergent research group at the IMIBIC, is to find those evidences that help to make decisions in the clinical setting to improve the diagnosis and the treatment of the patients with immune-mediated chronic inflammatory skin diseases of high prevalence or of special severity, such as psoriasis, atopic dermatitis, chronic urticaria, vitiligo, suppurative hidrosadenitis, and various chronic alopecias such as alopecia areata or frontal fibrosing alopecia.

Our group consists of 17 researchers: 10 Clinicians (5 Dermatologists, 3 Hospital Pharmacists, and 2 Nurses) and 7 non-clinicians (1 Study Coordinator, 3 BSc in Biology PhD candidates, 3 Medical Students).

Our group also promotes the participation of students of undergraduate, postgraduate, and physician specialists in training by means of collaboration with the degrees and postgraduate programs of Medicine, Chemical sciences, and Biotechnology (medical Education, MSc programs, PhD programs).

All research activities of the group are guided by our commitment to:

  • Encourage participation of citizens in observational studies and clinical trials promoted and participated by our group.
  • Promote actions that attract the R + D + I industry by offering collaborations in the form of service delivery models or co-development agreements of innovative ideas from results obtained by our group or from needs or problems found in relation to some research product of the industry itself.
  • Stimulate transversal collaboration with other research groups dedicated to areas such as applied physics, nanotechnology, and evidence synthesis or with other high level Spanish or foreign centers (Cochrane collaboration, Rockefeller University, Mount Sinai Hospital).
  • Communicate to other researchers and citizens the results obtained, through participation in scientific meetings, publications in journals and meetings with associations of patients and young people in training, who visit us regularly.
  • Collaborate with the other groups of the IMIBIC in generating talent in future generations of researchers, especially in those with clinical profile, through collaboration with the Degree and Postgraduate programs of the University of Cordoba and the University of Granada.

Research Lines

We use different technological platforms to analyze biological samples from patients and controls to explore the cellular and tissue functioning using multiscale approach (gene-expression analyses, miRNAs, circulating microparticles, cell cultures, and single-cell assays).

  • Since 2015 we have enrolled more than 83 patients and 86 healthy subjects to analyze clinical, biometrical, and skin and blood samples.
  • We have first deciphered the molecular profile of scalp psoriasis by immunohistochemical techniques, quantification and gene expression of molecules mediating inflammation.
  • We have recently created the PAIDI CTS-1041 Group "New diagnostic and therapeutic methods in immunomediated inflammatory skin diseases".
  • We have identified two proteins of the route JAK/STAT whose genes are overexpressed in the skin lesional and non-lesional of patients with vitiligo and others with fibrous frontal alopecia. The importance of these findings is that they are possible targets for therapies currently on the market and that have no indication approved for the treatment of these diseases.
  • We have stablished collaborative agreements for the development of research projects with Dr. Emma Guttman, director of the Ezcema Center and Laboratory of Inflammatory Skin diseases, Icahn School of Medicine Center at Mount Sinai New York (USA).
  • The PI is part of the expert panel of Scientific Project evaluators of the H2020-JTI-IMI2 program of the EU on genome-Environment interactions in Inflammatory Skin Disease.
  • Since 2012 we have enrolled more than 450 patients to analyze clinical, biometrical, dietary and exercise habits, and blood samples used to assess drug efficiency, to perform efficiency, economic, pharmacogenetic, and gene-environment interaction studies.
  • We have first described that STAT3 31313A > G (rs744166) polymorphism influences the metabolic syndrome phenotype and anti-TNFs response in women with moderate to severe plaque psoriasis.
  • We have also explored influencing seasonal patterns of relapse in anti-TNF psoriatic responders after temporary drug discontinuation.
  • Three PhD candidates are working on this research line.
  • We got founding to develop this research line from the Spanish National Institute of Health Carlos III (ISCIII) (ICI1400136/2015-2018 to JR).
  • We have established collaborative agreements for the development of research projects with Dr. J. Krueger, director of the Laboratory of Investigative Dermatology, the Rockefeller University, New York (USA), and Dr. Mayte Suárez-Fariñas, Associated Professor, Dept. of Population Health Science and Policy, Dept. of genetics and Genomics Science, Icahn Institute for Genomics and Multiscale Biology at Icahn School of Medicine Center at Mount Sinai New York (USA).

We evaluate the magnitude and quality of evidence about the efficacy and safety of drugs used for the treatment of skin diseases during clinical development phase.

  • We have compared the efficacy and safety of different biological treatments for moderate-severe psoriasis through systematic review and network meta-analysis and the results have been incorporated to the Clinical Practice Guideline for the Treatment of Psoriasis of the British Academy of Dermatology.
  • For the first time, we have described the influence of source of funding and conflict of interest of authors on the methodological quality of systematic reviews and meta-analyses about psoriasis.
  • During 2017 we published 8 systematic reviews or meta-epidemiological studies in D1/Q1 journals.
  • Two PhD candidates are working on this research line.
  • The group is integrated into and collaborates with the Cochrane Skin Group and the Cochrane Bias Method Group.
  • Our group has been recently granted by the Consejería de Salud (to JR) to develop a project titled “Proyecto Éaco: Desarrollo y validación de un instrumento tecnológico en red para el apoyo en la toma de decisiones en la práctica clínica (PIN-0316-2017)”.

We have participated in 10 clinical trials (phase II and Phase II), 3 observational studies and one independent clinical trial.

Project title: Cardiovascular risk factors in a Spanish population of patients with moderate-to-severe plaque psoriasis vulgaris, with or without associated psoriatic arthritis, treated with anti-TNF-α in real clinical practice. Analysis of the influence of Metabolic Syndrome on treatment efcacy. Principal Investigator: Juan Ruano.  (ClinicalTrials.gov ID: NCT01753245). Funded by Pfzer R&D's IIR program 2012.

Project title: Evaluación preclínica de la eficacia del compuesto CVX-785 y sus derivados en ensayos in vitro y modelos murinos de psoriasis (CDTI IDI20140274). Sponsor: Canvax S.L. Principal Investigator: Juan Ruano.

Project title: A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared with Placebo and Ustekinumab in Subjects with Moderate to Severe Plaque Psoriasis: AMAGINE-2. Sponsor: Amgen Inc. Principal Investigator: Juan Ruano.

Project title: Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment of Subjects With Moderate to Severe Plaque- type Psoriasis (VOYAGE 1). Sponsor: Janssen-Cilag. Principal Investigator: Juan Ruano. (ClinicalTrials.gov ID: NCT02207231)

Project title: Plaque Psoriasis Efficacy and Safety With Secukinumab (OPTIMISE). Sponsor: Novartis. Principal Investigator: Juan Ruano. (ClinicalTrials.gov ID: NCT02409667)

Project title: Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With Chronic Spontaneous Urticaria. Sponsor: Novartis. Principal Investigator: Juan Ruano.  (ClinicalTrials.gov ID: NCT02477332)

Project title: A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients. Sponsor: Novartis. Principal Investigator: Juan Ruano. (ClinicalTrials.gov ID: NCT02649218)

Project title: A multicentre, randomized, double-blind, parallel-group, controlled study, to assess the efficacy and safety of P-3074 cutaneous spray, solution, in the treatment of male pattern baldness. Sponsor: Polichem. Principal Investigator: Juan Ruano.  (EudraCT ID: 2015-002877-40)

Project title: Estudio Multicentrico de Fase 3, Aleatorizado, Doble Ciego para Evaluar la Eficacia Comparativa de Guselkumab (CNTO1959) y Secukinumab en el Tratamiento de la Psoriasis en Placa de Moderada a Grave (CNTO1959PSO3009)). Sponsor: Novartis. Principal Investigator: Juan Ruano. (EudraCT ID: 2016-002995-29)

Project title: A randomized, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy and safety of tralokinumab monotherapy in patients with moderate to severe atopic dermatitis who are candidates for systemic therapy ECZTRA-1 (LP0162-1325) Sponsor: Leo Pharma. Principal Investigator: Juan Ruano. (ClinicalTrials Id: NCT03131648)

Networks

Keywords

  • Immune-mediated skin diseases
  • psoriasis
  • atopic dermatitis
  • vitiligo
  • alopecia areata
  • genetic polymorphisms
  • biological therapies
  • cell culture
  • cold atmospheric plasma
  • cost-efficiency analyses
  • systematic reviews
  • meta-analyses
  • meta-epidemiology

Additional Information

Links


Featured Publications

We have published 90 articles in scientific journals and as communications to national and international scientific meetings, some of the last and outstanding are:

  • Ruano J, Gómez-GarcíaF, Gay-Mimbrera J, Aguilar-Luque M, Fernández-Rueda JL, Fernández-Chaichio J, Alcalde-Mellado P, Carmona-Fernandez PJ, Sanz-Cabanillas JL, Viguera-Guerra I, Franco-García F, Cárdenas-Aranzana M, Hernández Romero JL, Gonzalez-Padilla M, Isla-Tejera B, Velez Garcia-Nieto A. Evaluating characteristics of PROSPERO records as predictors of eventual publication of non-Cochrane systematic reviews: a meta-epidemiological study protocol. Systematic Reviews 2018 March [In press]
  • Gómez‐García F, Epstein D, Isla‐Tejera B, Lorente A, Vélez García‐Nieto A, Ruano J. Short‐term efficacy and safety of new biological agents targeting the interleukin‐23–T helper 17 pathway for moderate‐to‐severe plaque psoriasis: a systematic review and network meta‐analysis. British Journal of Dermatology. 2017 Mar 1;176(3):594-603.
  • Gómez-García F, Ruano J, Aguilar-Luque M, Alcalde-Mellado P, Gay-Mimbrera J, Hernández-Romero JL, Sanz-Cabanillas JL, Maestre-López B, González-Padilla M, Carmona-Fernández PJ, García-Nieto AV. Abstract analysis method facilitates filtering low-methodological quality and high-bias risk systematic reviews on psoriasis interventions. BMC medical research methodology. 2017 Dec;17(1):180.
  • Gómez-García F, Ruano J, Gay-Mimbrera J, Aguilar-Luque M, Sanz-Cabanillas JL, Alcalde-Mellado P, Maestre-López B, Carmona-Fernández PJ, González-Padilla M, García-Nieto AV, Isla-Tejera B. Most systematic reviews of high methodological quality on psoriasis interventions are classified as high risk of bias using ROBIS tool. Journal of clinical epidemiology. 2017 Dec 1;92:79-88.
  • Sanz-Cabanillas JL, Ruano J, Gomez-Garcia F, Alcalde-Mellado P, Gay-Mimbrera J, Aguilar-Luque M, Maestre-Lopez B, Gonzalez-Padilla M, Carmona-Fernandez PJ, Garcia-Nieto AV, Isla-Tejera B. Author-paper affiliation network architecture influences the methodological quality of systematic reviews and meta-analyses of psoriasis. PloS one. 2017 Apr 12;12(4):e0175419.
  • Gómez‐García F, Ruano J, Aguilar‐Luque M, Gay‐Mimbrera J, Maestre‐Lopez B, Sanz‐Cabanillas JL, Carmona‐Fernández PJ, González‐Padilla M, Vélez García‐Nieto A, Isla‐Tejera B. Systematic reviews and meta‐analyses on psoriasis: role of funding sources, conflict of interest and bibliometric indices as predictors of methodological quality. British Journal of Dermatology. 2017 Jun 1;176(6):1633-44.
  • Gay-Mimbrera J, García MC, Isla-Tejera B, Rodero-Serrano A, García-Nieto AV, Ruano J. Clinical and biological principles of cold atmospheric plasma application in skin cancer. Advances in therapy. 2016 Jun 1;33(6):894-909.
  • Ruano J, Suárez-Fariñas M, Shemer A, Oliva M, Guttman-Yassky E, Krueger JG. Molecular and cellular profiling of scalp psoriasis reveals differences and similarities compared to skin psoriasis. PloS one. 2016 Feb 5;11(2):e0148450.

Technology transfer

We have created a spin off on data mining called info4CURE that has obtained the AENOR quality certificate as Joven Empresa Innovadora (EA0043).

Awards

  • "Gonzalo Mino Fugarolas" award (to PI) for the best young researcher (2006), University of Cordoba, Spain.
  • "III Best Innovative Project Award IMIBIC-Roche 2016", Córdoba, Spain.
  • "Fellowship Infammatory Skin Disease Summit 2016", New York, USA.
  • "Premio Cátedra de psoriasis Universidad Autónoma de Madrid-Pfizer a la Mejor Publicación 2016 sobre Psoriasis o Artritis Psoriásica", Madrid, Spain.

Collaboration with technology-based companies

  • Canvax Biotech S.L.
  • Lynhce Diagnostics S.L.
  • ZebrafishLab S.L.

GE03 Inflammatory immune-mediated cutaneous diseases

Principal Investigator
Juan Ruano Ruiz

Researchers
Francisco Franco García
José Luis Hernández Romero

Post-Doctoral Researchers
Francisco José Gómez García
Marcelino González Padilla
Antonio Vélez García-Nieto
Beatriz Isla Tejera

Pre-Doctoral Researchers
Macarena Aguilar Luque
Pedro Jesús Carmona Fernández
Jesús Gay Mimbrera
Pedro Jesús Gómez Arias
Juan Luis Sanz Cabanillas
Isabel Viguera Guerra

Students of Medicine
Patricia Alcalde Mellado
Beatriz Maestre López
Ana María Montilla López

Other members of the team
Maríadel Carmen Clemente Milla
María López García
Carmen López González

Projects

Active projects

Regional

Ruano Ruiz, J. Éaco Project: Development and validation of a technological network instrument for support in decision making in clinical practice. Funding agency: Regional Ministry of Health and Social Policy (CISPS). Funding Agency: PIN-0316-2017

Aguilar Luque, M. Comparación De Las Revisiones Sistemáticas Publicada Con Su Protocolo Registrado En Prospero. Funding Agency: FIBICO. Reference: EF-0399-2018-FIB

Gay Mimbrera, J; Elucidación Del Perfil Molecular Del Cuero Cabelludo De Pacientes Con Alopecia Frontal Fibrosante. Funding Agency: FIBICO. Reference: EF-0400-2018-FIB

National

Ruano Ruiz, J. Ensayo clínico aleatorizado y multicéntrico para evaluar, en términos de coste-eficiencia, un modelo predictivo de respuesta a fármacos anti-TNFs en psoriasis moderada-severa. Funding agency: National Institute of Health Carlos III (ISCIII). Reference: ICI14/00136

Publications

Publications 2019

Zhou LS, Leonard A, Pavel AB, Malik K, Raja A, Glickman J, Estrada YD, Peng XY, del Duca E, Sanz-Cabanillas J, Ruano J, Xu H, Zhang N, Wen HC, Gonzalez J, Garcet S, Krueger JG, Guttman-Yassky E; Age-specific changes in the molecular phenotype of patients with moderate-to-severe atopic dermatitis. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. 2019 Jul;144(1):144-156. doi: 10.1016/j.jaci.2019.01.015.
IF: 14,11
D: 1

Barbarroja N, Arias-de la Rosa I, Lopez-Medina C, Camacho-Sanchez MD, Gomez-Garcia I, Velez-Garcia AJ, Escudero-Contreras A, Lopez-Pedrera C, Lopez-Montilla MD, Collantes-Estevez E; Cardiovascular risk factors in psoriatic disease: psoriasis versus psoriatic arthritis. THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE. 2019 Oct 16;11:1759720X19880742. doi: 10.1177/1759720X19880742. 
IF: 5,045
Q: 1 D: 2 
  
Montilla AM, Gomez-Garcia F, Gomez-Arias PJ, Gay-Mimbrera J, Hernandez-Parada J, Isla-Tejera B, Ruano J; Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata. DERMATOLOGY AND THERAPY. 2019 Dec;9(4):655-683. doi: 10.1007/s13555-019-00329-y.
IF: 3,615
Q: 1 D: 2 
     
Alcantara-Reifs CM, Salido-Vallejo R, Garnacho-Saucedo GM, Garcia-Nieto AV; Dome-shaped nodules and scaly, verruciform plaques on the legs and feet. INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY. 2019 Mar-Apr;85(2):226-228. doi: 10.4103/ijdvl.IJDVL_255_17. 
IF: 3,03
Q: 2 

Viguera-Guerra I, Ruano J, Aguilar-Luque M, Gay-Mimbrera J, Montilla A, Fernandez-Rueda JL, Fernandez-Chaichio J, Sanz-Cabanillas JL, Gomez-Arias PJ, Garcia-Nieto AV, Gomez-Garcia F, Isla-Tejera B; Evolution of international collaborative research efforts to develop non-Cochrane systematic reviews. PLOS ONE. 2019 Feb 27;14(2):e0211919. doi: 10.1371/journal.pone.0211919.
IF: 2,776
Q: 2

Gomez-Garcia F, Gomez-Arias PJ, Hernandez J, Montilla AM, Gay-Mimbrera J, Aguilar-Luque M, Viguera-Guerra I, Garcia-Nieto AV, Isla-Tejera B, Ruano J; Drugs targeting the JAK/STAT pathway for the treatment of immune-mediated inflammatory skin diseases: protocol for a scoping review. BMJ OPEN. 2019 May 22;9(5):e028303. doi: 10.1136/bmjopen-2018-028303. 
IF: 2,413
Q: 2 

Moreno-Arrones OM, Saceda-Corralo D, Rodrigues-Barata AR, Castellanos-Gonzalez M, Fernandez-Pugnaire MA, Grimalt R, Hermosa-Gelbard A, Bernardez C, Molina-Ruiz AM, Ormaechea-Perez N, Fernandez-Crehuet P, Vano-Galvan S; Risk factors associated with frontal fibrosing alopecia: a multicentre case-control study. CLINICAL AND EXPERIMENTAL DERMATOLOGY. 2019 Jun;44(4):404-410. doi: 10.1111/ced.13785.
IF: 1,771
Q: 3 

Main Publications 2018

Ruano J, Gomez-Garcia F, Gay-Mimbrera J, Aguilar-Luque M, Fernandez-Rueda JL, Fernandez-Chaichio J, Alcalde-Mellado P, Carmona-Fernandez PJ, Sanz-Cabanillas JL, Viguera-Guerra I, Franco-Garcia F, Cardenas-Aranzana M, Romero JLH, Gonzalez-Padilla M, Isla-Tejera B, Garcia-Nieto AV. Evaluating characteristics of PROSPERO records as predictors of eventual publication of non-Cochrane systematic reviews: a meta-epidemiological study protocol. SYSTEMATIC REVIEWS. 2018; 7: Núm artículo 43
IF: 6,754  
Q: 1   D: 1

Ruano J, Aguilar-Luque M, Isla-Tejera B, Alcalde-Mellado P, Gay-Mimbrera J, Hernandez-Romero JL, Sanz-Cabanillas JL, Maestre-Lopez B, Gonzalez-Padilla M, Carmona-Fernandez PJ, Gomez-Garcia F, Garcia-Nieto AV. Relationships between abstract features and methodological quality explained variations of social media activity derived from systematic reviews about psoriasis interventions. JOURNAL OF CLINICAL EPIDEMIOLOGY. 2018; 101:35-43.
IF: 4,245  
Q: 1

Gomez-Garcia F, Sanz-Cabanillas JL, Viguera-Guerra I, Isla-Tejera B, Nieto AVG, Ruano J. Scoping Review on Use of Drugs Targeting Interleukin 1 Pathway in DIRA and DITRA. DERMATOLOGY AND THERAPY. 2018; 8(4):539-556.
IF: 3,620   
Q: 1

Gomez-Garcia F, Ruano J, Gay-Mimbrera J, Aguilar-Luque M, Sanz-Cabanillas JL, Romero JLH, Garcia-Nieto AV. A Scoping Review Protocol to Explore the Use of Interleukin-1-Targeting Drugs for the Treatment of Dermatological Diseases: Indications, Mechanism of Action, Efficacy, and Safety. DERMATOLOGY AND THERAPY. 2018; 8(2):195-202.
IF: 3,620   
Q: 1

Ruano J, Aguilar-Luque M, Gomez-Garcia F, Mellado PA, Gay-Mimbrera J, Carmona-Fernandez PJ, Maestre-Lopez B, Sanz-Cabanillas JL, Romero JLH, Gonzalez-Padilla M, Garcia-Nieto AV, Isla-Tejera B. The differential impact of scientific quality, bibliometric factors, and social media activity on the influence of systematic reviews and meta-analyses about psoriasis. PLOS ONE. 2018; 13(1): Núm artículo e0191124
IF: 2,766  
Q: 1

Gonzalez-Cantero A, Carretero G, Rivera R, Ferrandiz C, Dauden E, de la Cueva P, Gomez-Garcia FJ, Belinchon I, Herrera-Ceballos E, Ruiz-Genao D, Ferran M, Alsina M, Sanchez-Carazo JL, Baniandres O, Sahuquillo-Torralba A, Rodriguez L, Vilar J, Garcia C, Carrascosa JM, Llamas-Velasco M, Herrera-Acosta E, Lopez-Estebaranz JL, Botella-Estrada R, Descalzo MA, Garcia-Doval I; Women with moderate-to-severe psoriasis in Spain (BIOBADADERM registry) show more than a 50% reduction in age-adjusted fertility rate when compared with the general population. BRITISH JOURNAL OF DERMATOLOGY. 2019 Nov;181(5):1085-1087. doi: 10.1111/bjd.18164.
IF: 6,714.
D:1 Q:1

Other Publications 2018

Descalzo MA, Carretero G, Ferrandiz C, Rivera R, Dauden E, Gomez-Garcia FJ, de la Cueva P, Herrera-Ceballos E, Belinchon I, Lopez-Estebaranz JL, Alsina M, Sanchez-Carazo JL, Ferran M, Baniandres O, Carrascosa JM, Llamas-Velasco M, Ruiz-Genao D, Herrera-Acosta E, Munoz-Santos C, Garcia-Doval I. Change over time in the rates of adverse events in patients receiving systemic therapy for psoriasis: A cohort study. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2018; 78(4):798-800.
IF: 6,898 
Q: 1   D: 1

Garcia-Doval I, Descalzo MA, Mason KJ, Cohen AD, Ormerod AD, Gomez-Garcia FJ, Cazzaniga S, Feldhamer I, Ali H, Herrera-Acosta E, Griffiths CEM, Stern RS, Naldi L. Cumulative exposure to biological therapy and risk of cancer in patients with psoriasis: a meta-analysis of Psonet studies from Israel, Italy, Spain, the UK and Republic of Ireland. BRITISH JOURNAL OF DERMATOLOGY. 2018; 179(4):863-871.
IF: 6,129  
Q: 1   D: 1

Escribano BM, Aguera E, Aguilar-Luque M, Luque E, Feijoo M, LaTorre M, Giraldo AI, Galvan-Jurado A, Caballero-Villarraso J, Garcia-Maceira FI, Santamaria A, Tunez I. Neuroprotective effect of S-allyl cysteine on an experimental model of multiple sclerosis: Antioxidant effects. JOURNAL OF FUNCTIONAL FOODS. 2018; 42:281-288.
F: 3,47  
Q: 1

Hernandez GC, Ferrandiz C, Diaz RR, Tello ED, de la Cueva-Dobao P, Gomez-Garcia FJ, Herrera-Ceballos E, Romero IB, Lopez-Estebaranz JL, Gibert MA, Sanchez-Carazo JL, Farres MF, Quesada AG, Carrillo JMC, Llamas-Velasco M, Fernandez MVM, Genao DR, Santos CM, Garcia-Doval I, Descalzo MA. Description of Patients Treated with Biologic Drugs as First-Line Systemic Therapy in the BIOBADADERM Registry Betwswn 2008 and 2016. ACTAS DERMO-SIFILIOGRAFICAS. 2018; 109(7):617-623.
IF: 0

Main Publications 2017

Gomez-Garcia F, Ruano J, Gay-Mimbrera J, Aguilar-Luque M, Sanz-Cabanillas JL, Alcalde-Mellado P, Maestre-Lopez B, Carmona-Fernandez PJ, Gonzalez-Padilla M, Garcia-Nieto AV, Isla-Tejera B. Most systematic reviews of high methodological quality on psoriasis interventions are classified as high risk of bias using ROBIS tool. JOURNAL OF CLINICAL EPIDEMIOLOGY. 2017.92():79-88.
IF: 4,978
Q: 1  D: 1

Gomez-Garcia F, Epstein D, Isla-Tejera B, Lorente A, Garcia-Nieto AV, Ruano J. Short-term efficacy and safety of new biological agents targeting the interleukin-23-T helper 17 pathway for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis. BRITISH JOURNAL OF DERMATOLOGY. 2017.176(3):594-603.
IF: 4,706
Q: 1  D:1

Gomez-Garcia F, Ruano J, Aguilar-Luque M, Gay-Mimbrera J, Maestre-Lopez B, Sanz-Cabanillas JL, Carmona-Fernandez PJ, Gonzalez-Padilla M, Garcia-Nieto AV, Isla-Tejera B.  Systematic reviews and meta-analyses on psoriasis: role of funding sources, conflict of interest and bibliometric indices as predictors of methodological quality. BRITISH JOURNAL OF DERMATOLOGY. 2017.176(6):1633-1644.
IF: 4,706
Q: 1  D:1

Gomez-Garcia F, Ruano J, Aguilar-Luque M, Alcalde-Mellado P, Gay-Mimbrera J, Hernandez-Romero JL, Sanz-Cabanillas JL, Maestre-Lopez B, Gonzalez-Padilla M, Carmona-Fernandez PJ, Garcia-Nieto AV, Isla-Tejera B. Abstract analysis method facilitates filtering low-methodological quality and high-bias risk systematic reviews on psoriasis interventions. BMC MEDICAL RESEARCH METHODOLOGY. 2017.17():-180.
IF: 3,295
Q: 1 

Sanz-Cabanillas JL, Ruano J, Gomez-Garcia F, Alcalde-Mellado P, Gay-Mimbrera J, Aguilar-Luque M, Maestre-Lopez B, Gonzalez-Padilla M, Carmona-Fernandez PJ, Garcia-Nieto AV, Isla-Tejera B. Author-paper affiliation network architecture influences the methodological quality of systematic reviews and meta-analyses of psoriasis. PLOS ONE. 2017.12(4):-e0175419.
IF: 2,806
Q: 1 

Gay-Mimbrera J, Garcia MC, Isla-Tejera B, Rodero-Serrano A, Garcia-Nieto AV, Ruano J.  Clinical and Biological Principles of Cold Atmospheric Plasma Application in Skin Cancer (vol 33, pg 894, 2016). ADVANCES IN THERAPY. 2017.34(1):280-280.
IF: 2,709
Q: 2 

Other Publications 2017

Davila-Seijo P, Dauden E, Descalzo MA, Carretero G, Carrascosa JM, Vanaclocha F, Gomez-Garcia FJ, de la Cueva-Dobao P, Herrera-Ceballos E, Belinchon I, Lopez-Estebaranz JL, Alsina M, Sanchez-Carazo JL, Ferran M, Torrado R, Ferrandiz C, Rivera R, Llamas M, Jimenez-Puya R, Garcia-Doval I, BIOBADADERM Study Grp. Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry. JOURNAL OF INVESTIGATIVE DERMATOLOGY.  2017.137(2):313-321.
IF: 6,287
Q: 1  D: 1

Belinchon I, Ramos JM, Carretero G, Ferrandiz C, Rivera R, Dauden E, De la Cueva-Dobao P, Gomez-Garcia FJ, Herrera-Ceballos E, Sanchez-Carazo JL, Lopez-Estebaranz JL, Alsina M, Ferran M, Torrado R, Carrascosa JM, Llamas-Velasco M, Ortiz PL, Garcia-Doval I, Descalzo MA, Biobadaderm Study Grp. Adverse events associated with discontinuation of the biologics/classic systemic treatments for moderate-to-severe plaque psoriasis: data from the Spanish Biologics Registry, Biobadaderm. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2017.31(10):1700-1708.
IF: 3,528
Q: 1 

Perez-Plaza A, Carretero G, Ferrandiz C, Vanaclocha F, Gomez-Garcia FJ, Herrera-Ceballos E, De la Cueva-Dobao P, Belinchon I, Sanchez-Carazo JL, Alsina M, Lopez-Estebaranz JL, Ferran M, Torrado R, Carrascosa JM, Llamas-Velasco M, Rivera R, Jimenez-Puya R, Garcia-Doval I, Descalzo MA, Biobadaderm Study Grp. Comparison of phenotype, comorbidities, therapy and adverse events between psoriatic patients with and without psoriatic arthritis. Biobadaderm registry. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2017.31(6):1021-1028.
IF: 3,528
Q: 1 

Mejias SG, Carretero G, Ferrandiz C, Vanaclocha F, Dauden E, Gomez-Garcia FJ, Herrera-Ceballos E, Belinchon-Romero I, Sanchez-Carazo JL, Lopez-Estebaranz JL, Alsina M, Ferran M, Torrado R, Carrascosa JM, Rivera R, Llamas-Velasco M, Jimenez-Puya R, Mendiola MV, Ruiz-Genao D, Descalzo MA, de la Cueva Dobao P, del grupo Biobadaderm. Management of Biologic Therapy In Moderate to Severe Psoriasis in Surgical Patients: Data From the Spanish Biobadaderm registry. ACTAS DERMO-SIFILIOGRAFICAS. 2017.108(1):52-58.

Escribano BM, Luque E, Aguilar-Luque M, Feijóo M, Caballero-Villarraso J, Torres LA, Ramirez V, García-Maceira FI, Agüera E, Santamaria A, Túnez I. Dose-dependent S-allyl cysteine ameliorates multiple sclerosis disease-related pathology by reducing oxidative stress and biomarkers of dysbiosis in experimental autoimmune encephalomyelitis. Eur J Pharmacol. 2017 Nov 15;815:266-273
IF: 2,896
Q: 2

Medina-Fernandez FJ, Escribano BM, Agüera E, Aguilar-Luque M, Feijoo M, Luque  E, Garcia-Maceira FI, Pascual-Leone A, Drucker-Colin R, Tunez I. Effects of transcranial magnetic stimulation on oxidative stress in experimental autoimmune  encephalomyelitis. Free Radic Res. 2017 May;51(5):460-469
IF: 3,188
Q: 2

Medina-Fernández FJ, Luque E, Aguilar-Luque M, Agüera E, Feijóo M, García-Maceira FI, Escribano BM, Pascual-Leone Á, Drucker-Colín R, Túnez I. Transcranial magnetic stimulation modifies astrocytosis, cell density and lipopolysaccharide levels in experimental autoimmune encephalomyelitis. Life Sci. 2017 Jan 15;169:20-26
IF: 2,936
Q: 2

Alcantara-Reifs CM, Garnacho-Saucedo G, Salido-Vallejo R, Velez Garcia-Nieto A. Topical Amphotericin B for the treatment of localized cutaneous leishmaniasis. DERMATOLOGIC THERAPY. 2017.30(1):-UNSP e12402.
IF: 1,093
Q: 4 

Escribano BM, Medina-Fernández FJ, Aguilar-Luque M, Agüera E, Feijoo M, Garcia-Maceira FI, Lillo R, Vieyra-Reyes P, Giraldo AI, Luque E, Drucker-Colín R, Túnez I.  Lipopolysaccharide Binding Protein and Oxidative Stress in a Multiple Sclerosis Model.  Neurotherapeutics. 2017 Jan;14(1):199-211
IF: 5,166
Q: 1

Clinical Research

Active in 2019

Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis.
PI: Dr. Juan Ruano

A Phase 3, Multicenter, Randomized, Double-blind Study Evaluating the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis.
PI: Dr. Juan Ruano

A randomized double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy and safety to tralokinumab monotherapy in patients with moderate to sever atopic dermatitis who are candidates for systemic therapy.
PI: Dr. Juan Ruano

Open clinical study to evaluate the efficacy and long-term safety of dimethyl fumarate in adults with chronic moderate to severe plaque psoriasis in clinical practice (Estudio DIMESKIN 1).
PI: Dr. Antonio Vélez García-Nieto

Estudio multicéntrico, aleatorizado, con doble enmascaramiento y controlado con placebo, para evaluar la eficacia y seguridad de mirikizumab con secukinumab y placebo en pacientes con psoriasis en placas moderada a grave. OASIS-2.
PI: Dr. Juan Ruano

Estudio en fase iii de retirada aleatorizada, doble ciego, controlado con placebo y multicéntrico para investigar la eficacia y la seguridad de pf-04965842 en pacientes de 12 o más años de edad con dermatitis atópica moderada o grave con la opción de un tratamiento de rescate para aquellos pacientes que presenten un empeoramiento de la enfermedad.
PI: Dr. Juan Ruano

Estudio de fase III, multicéntrico, aleatorizado, doble ciego y comparado con placebo, para evaluar la eficacia y la seguridad de baricitinib en combinación con corticoesteroides de administración tópica en pacientes adultos con dermatitis atópica de moderada a grave - BREEZE - AD7.
PI: Dr. Juan Ruano

Estudio de fase IIa multicéntrico, aleatorizado, doble ciego, con control activo y placebo para investigar la eficacia y seguridad de ligelizumab (QGE031) en el tratamiento de la urticaria crónica espontánea (UCE) en adolescentes y adultos inadecuadamente controlada con antihistamínicos H1.
PI: Dr. Juan Ruano

Ensayo de extensión a largo plazo, multicéntrico, abierto y de un solo brazo, para evaluar la seguridad y eficacia de tralokinumab en pacientes con dermatitis atópica que participaron previamente en ensayos clínicos con tralokinumab.
PI: Dr. Juan Ruano Ruiz

Estudio en fase III multicéntrico y de extensión a largo plazo para evaluar la eficacia y la seguridad de PF-04965842, en monoterapia o en combinación con medicamentos tópicos, administrado a pacientes de 12 años o más con dermatitis atópica moderada o grave.
PI: Dr. Juan Ruano

Ensayo aleatorizado, doble ciego, controlado con placebo, de grupos paralelos, multicéntrico, de fase 3 que investiga la eficacia, la seguridad y la tolerabilidad de tralokinumab administrado en combinación con corticosteroides tópicos a pacientes adultos con dermatitis atópica grave que no están suficientemente controlados con ciclosporina A oral o para los que este fármaco está contraindicado.
PI: Dr. Juan Ruano

Estudio de fase IIa, aleatorizado, con doble enmascaramiento, controlado con placebo, de grupos paralelos y multicéntrico de un anticuerpo monoclonal anti-OX40L (KY1005) en la dermatitis atópica de moderada a grave.
PI: Dr. Juan Ruano

A phase 2B randomnized, double blind, placebo controlled, multicenter, dose ranging study to evaluate the efficacy and safety profile of PF-06651600 with a partially blinded extension period to evaluate the efficacy and safety of PF-06651600 and PF-06700841 in subjects with active non segmental vitiligo.
PI: Dr. Juan Ruano

Estudio de fase III, multicéntrico, aleatorizado, doble ciego, controlado con placebo y un fármaco activo, de interrupción y reinicio aleatorizado del tratamiento para evaluar la eficacia y seguridad de BMS-986165 en pacientes con psoriasis en placas de m.
PI: Dr. Juan Ruano Ruiz

Estudio de fase 3, multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de apremilast (CC-10004) en pacientes pediátricos de 6 a 17 años con psoriasis en placas de moderada a grave.
PI: Dr. Juan Ruano Ruiz

Randomized, double- blind, Placebo controlled, Multicenter trial to Evaluate the efficacy and of oral BtK Inhibitor PRN1008 in Moderate to Severe Pemphigus.
PI: Dr. Juan Ruano Ruiz

Estudio de fase II b, aleatorizado, en doble ciego, controlado con placebo, de grupos paralelos y de búsqueda de dosis, para investigar los perfiles de eficacia, seguridad y farmacocinética de REGN3500 en pacientes adultos con dermatitis atópica moderada .
PI: Dr. Juan Ruano Ruiz

Estudio fase 3, doble ciego, aleatorizado, controlado con vehículo, sobre la eficacia y seguridad del tratamiento con Ruxolitinib en crema, en adolescentes y adultos con dermatitis atópica, de 8 semanas de duración seguido de un periodo de extensión de se.
PI: Dr. Juan Ruano Ruiz

Members

Team

Francisco Franco García, José Luis Hernández Romero, Francisco José Gómez García, Marcelino González Padilla, Antonio Vélez García-Nieto, Beatriz Isla Tejera, Macarena Aguilar Luque, Pedro Jesús Carmona Fernández, Jesús Gay Mimbrera, Pedro Jesús Gómez Arias, Juan Luis Sanz Cabanillas, Isabel Viguera Guerra, Patricia Alcalde Mellado, Beatriz Maestre López, Ana María Montilla López, Maríadel Carmen Clemente Milla, María López García, Carmen López González